CSChrista Studzinski

Christa Studzinski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christa Studzinski has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From community to policy: a frontline model for dementia assessment and brain health

    by Kyle DeDecker, Ngozi Iroanyah, Adam Morrison, Julie Datta, Ibukun-Oluwa Omolade Omolade Abejirinde, Caitlin R. Siu, Christina Stergiou-Dayment, Shawn Paron, Christa M. M Studzinski

    Globally, dementia prevalence is projected to rise from approximately 55 million people in 2025 to 139 million by 2050. In Ontario, prevalence is estimated to reach 756,100 people by 2050—an increase of 202% since 2020—placing increasing strain on care partners, families, and health systems (Alzheimer Society of Canada, 2022). Throughout Ontario and Canada more broadly, existing pathways for cognitive screening, assessment, and diagnosis are constrained by limited primary care capacity, prolonged specialist wait times, and inequitable access, leaving many individuals without timely assessment or connection to supports. To help address these gaps, the Alzheimer Society of Ontario (ASO) and the Ontario Brain Institute (OBI) leveraged an existing community-delivered cognitive assessment process and enhanced it through the co-development of a provincial dementia registry—the first of its kind in Canada. This novel integrated approach embeds structured cognitive and functional assessment within community organizations, shares assessment results with primary care, and links standardized data to a provincial registry infrastructure. Together, this supports timely identification of cognitive concerns and enables the collection of a standardized minimum dataset—including cognitive, functional, demographic, and care-related information—across diverse populations. The dementia registry can serve as infrastructure to evaluate dementia-related innovations (including digital cognitive-screening tools) in real-world settings and support evidence generation to inform service planning and policy development, while strengthening earlier connection to supports and more coordinated care pathways for individuals and their care partners. This approach is aligned with emerging regulatory emphasis on real-world evidence (U.S. Food and Drug Administration, 2018; European Medicines Agency, 2021; Health Canada, 2019) and with Ontario’s Improving Dementia Care in Ontario Act (2024), illustrating how co-designed, frontline-led approaches may bridge community needs and health system decision-making. Together, this work lays the groundwork for a scalable framework to advance equitable, person-centred dementia care in Ontario and beyond.

  • Open Access

    Beyond the Lab: Scaling Wearables for Real‐World Impact through Partnerships and Implementation

    by Christa Studzinski

    Despite the advancement of wearable technologies, widespread adoption and implementation of these potentially transformative technologies to support aging individuals, including those with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD), has yet to be achieved. This barrier to adoption has prevented us from fully realizing the potential transformative impact wearables could have – both in the delivery of compassionate and accessible dementia care and in improving outcomes for aging individuals. This session will share lessons learned from the Ontario Brain Institute's journey to co‐design and launch a program called CORTEX (Community‐led Real‐world neuroTech Experience) that empowers community groups and people with lived experience in testing, implementing, and scaling wearable technology. We will share how the initial concept for CORTEX emerged, how the program was initially co‐designed with community groups and people with lived experience, and the learnings from the first pilots conducted in partnership with patient groups. Finally, we will show how the learnings informed the launch of our flagship CORTEX initiative, the Canadian Dementia Registry, which was co‐created in partnership with the Alzheimer Society of Ontario. This registry allows us to (1) understand the earliest stage of the dementia journey diagnosis (including how conducting cognitive assessments in the community, on behalf of primary care practitioners fills an early detection gap), (2) test neurotechnologies in diverse populations and compare them to clinically‐relevant scales (e.g., MoCA), and (3) look at how these technologies can fit into the care pathway in local communities so that we can increase access to the right clinicians and care they need and deserve.

  • Open Access

    Beyond the Lab: Scaling Wearables for Real‐World Impact through Partnerships and Implementation

    by Christa Studzinski

    Despite the advancement of wearable technologies, widespread adoption and implementation of these potentially transformative technologies to support aging individuals, including those with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD), has yet to be achieved. This barrier to adoption has prevented us from fully realizing the potential transformative impact wearables could have – both in the delivery of compassionate and accessible dementia care and in improving outcomes for aging individuals. This session will share lessons learned from the Ontario Brain Institute's journey to co‐design and launch a program called CORTEX (Community‐led Real‐world neuroTech Experience) that empowers community groups and people with lived experience in testing, implementing, and scaling wearable technology. We will share how the initial concept for CORTEX emerged, how the program was initially co‐designed with community groups and people with lived experience, and the learnings from the first pilots conducted in partnership with patient groups. Finally, we will show how the learnings informed the launch of our flagship CORTEX initiative, the Canadian Dementia Registry, which was co‐created in partnership with the Alzheimer Society of Ontario. This registry allows us to (1) understand the earliest stage of the dementia journey diagnosis (including how conducting cognitive assessments in the community, on behalf of primary care practitioners fills an early detection gap), (2) test neurotechnologies in diverse populations and compare them to clinically‐relevant scales (e.g., MoCA), and (3) look at how these technologies can fit into the care pathway in local communities so that we can increase access to the right clinicians and care they need and deserve.

  • Open Access

    Beyond the Lab: Scaling Wearables for Real‐World Impact through Partnerships and Implementation

    by Christa Studzinski

    Despite the advancement of wearable technologies, widespread adoption and implementation of these potentially transformative technologies to support aging individuals, including those with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD), has yet to be achieved. This barrier to adoption has prevented us from fully realizing the potential transformative impact wearables could have – both in the delivery of compassionate and accessible dementia care and in improving outcomes for aging individuals. This session will share lessons learned from the Ontario Brain Institute's journey to co‐design and launch a program called CORTEX (Community‐led Real‐world neuroTech Experience) that empowers community groups and people with lived experience in testing, implementing, and scaling wearable technology. We will share how the initial concept for CORTEX emerged, how the program was initially co‐designed with community groups and people with lived experience, and the learnings from the first pilots conducted in partnership with patient groups. Finally, we will show how the learnings informed the launch of our flagship CORTEX initiative, the Canadian Dementia Registry, which was co‐created in partnership with the Alzheimer Society of Ontario. This registry allows us to (1) understand the earliest stage of the dementia journey diagnosis (including how conducting cognitive assessments in the community, on behalf of primary care practitioners fills an early detection gap), (2) test neurotechnologies in diverse populations and compare them to clinically‐relevant scales (e.g., MoCA), and (3) look at how these technologies can fit into the care pathway in local communities so that we can increase access to the right clinicians and care they need and deserve.

  • Open Access

    Testing a New Approach to Monitor Mild Cognitive Impairment and Cognition in Older Adults at the Community Level

    by Isabel Paniak, Ethan Cohen, Christa Studzinski, Lia Tsotsos

    Dementia and mild cognitive impairment (MCI) are growing health concerns in Canada’s aging population. Over 700,000 Canadians currently live with dementia, and this number is expected to rise. As the older adult population increases, coupled with an already strained healthcare system, there is a pressing need for innovative tools that support aging in place. This study explored the feasibility and acceptability of using a Digital Human (DH) conversational agent, combined with AI-driven speech analysis, to monitor cognitive function, anxiety, and depression in cognitively healthy community-dwelling older adults (CDOA) aged 65 and older. Sixty older adults participated in up to three in-person sessions over six months, interacting with the DH through journaling and picture description tasks. Afterward, 51 of the participants completed structured interviews about their experiences and perceptions of the DH and AI more generally. Findings showed that 84% enjoyed interacting with the DH, and 96% expressed interest in learning more about AI in healthcare. While participants were open and curious about AI, 67% voiced concerns about AI replacing human interaction in healthcare. Most found the DH friendly, though reactions to its appearance varied. Overall, participants viewed AI as a promising tool, provided it complements, rather than replaces, human interactions.


  • Open Access

    Testing a New Approach to Monitor Mild Cognitive Impairment and Cognition in Older Adults at the Community Level

    by Isabel Paniak, Ethan Cohen, Christa Studzinski, Lia Tsotsos

    Dementia and mild cognitive impairment (MCI) are growing health concerns in Canada’s aging population. Over 700,000 Canadians currently live with dementia, and this number is expected to rise. As the older adult population increases, coupled with an already strained healthcare system, there is a pressing need for innovative tools that support aging in place. This study explored the feasibility and acceptability of using a Digital Human (DH) conversational agent, combined with AI-driven speech analysis, to monitor cognitive function, anxiety, and depression in adults aged 65 and older with and without MCI. Sixty older adults participated in up to three in-person sessions over six months, interacting with the DH through journaling and picture description tasks. Afterward, 51 of the participants completed structured interviews about their experiences and perceptions of the DH and AI more generally. Findings showed that 84% enjoyed interacting with the DH, and 96% expressed interest in learning more about AI in healthcare. While participants were open and curious about AI, 55% expressed concerns about AI replacing human healthcare providers. Most found the DH friendly, though reactions to its appearance varied. Overall, participants viewed AI as a promising tool, provided it complements, rather than replaces, human interactions.